Advertisement

Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT

Published:October 02, 2018DOI:https://doi.org/10.1053/j.ajkd.2018.07.015

      Background

      Random assignment to the intensive systolic blood pressure (SBP) arm (<120 mm Hg) in the Systolic Blood Pressure Intervention Trial (SPRINT) resulted in more rapid declines in estimated glomerular filtration rates (eGFRs) than in the standard arm (SBP < 140 mm Hg). Whether this change reflects hemodynamic effects or accelerated intrinsic kidney damage is unknown.

      Study Design

      Longitudinal subgroup analysis of clinical trial participants.

      Settings & Participants

      Random sample of SPRINT participants with prevalent chronic kidney disease (CKD) defined as eGFR < 60 mL/min/1.73 m2 by the CKD-EPI (CKD Epidemiology Collaboration) creatinine-cystatin C equation at baseline.

      Outcomes & Measurements

      Urine biomarkers of tubule function (β2-microglobulin [B2M], α1-microglobulin [A1M]), and uromodulin), injury (interleukin 18, kidney injury molecule 1, and neutrophil gelatinase-associated lipocalin), inflammation (monocyte chemoattractant protein 1), and repair (human cartilage glycoprotein 40) at baseline, year 1, and year 4. Biomarkers were indexed to urine creatinine concentration and changes between arms were evaluated using mixed-effects linear models and an intention-to-treat approach.

      Results

      978 SPRINT participants (519 in the intensive and 459 in the standard arm) with prevalent CKD were included. Mean age was 72 ± 9 years and eGFR was 46.1 ± 9.4 mL/min/1.73 m2 at baseline. Clinical characteristics, eGFR, urinary albumin-creatinine ratio, and all 8 biomarker values were similar across arms at baseline. Compared to the standard arm, eGFR was lower by 2.9 and 3.3 mL/min/1.73 m2 in the intensive arm at year 1 and year 4. None of the 8 tubule marker levels was higher in the intensive arm compared to the standard arm at year 1 or year 4. Two tubule function markers (B2M and A1M) were 29% (95% CI, 10%-43%) and 24% (95% CI, 10%-36%) lower at year 1 in the intensive versus standard arm, respectively.

      Limitations

      Exclusion of persons with diabetes, and few participants had advanced CKD.

      Conclusions

      Among participants with CKD in SPRINT, random assignment to the intensive SBP arm did not increase any levels of 8 urine biomarkers of tubule cell damage despite loss of eGFR. These findings support the hypothesis that eGFR declines in the intensive arm of SPRINT predominantly reflect hemodynamic changes rather than intrinsic damage to kidney tubule cells.

      Graphical Abstract

      Index Words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lewington S.
        • Clarke R.
        • Qizilbash N.
        • et al.
        Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
        Lancet. 2002; 360: 1903-1913
        • Vasan R.S.
        • Larson M.G.
        • Leip E.P.
        • et al.
        Impact of high-normal blood pressure on the risk of cardiovascular disease.
        N Engl J Med. 2001; 345: 1291-1297
        • Zanchetti A.
        Hypertension-related mortality and morbidity.
        J Hypertens. 2015; 33: 1979-1980
        • James P.A.
        • Oparil S.
        • Carter B.L.
        • et al.
        2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
        JAMA. 2014; 311: 507-520
        • Neal B.
        • MacMahon S.
        • Chapman N.
        • et al.
        Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.
        Lancet. 2000; 356: 1955-1964
        • Malhotra R.
        • Nguyen H.A.
        • Benavente O.
        • et al.
        Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis.
        JAMA Intern Med. 2017; 177: 1498-1505
        • Hirsch S.
        • Hirsch J.
        • Bhatt U.
        • et al.
        Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success.
        Am J Nephrol. 2012; 36: 430-437
        • Klahr S.
        • Levey A.S.
        • Beck G.J.
        • et al.
        The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
        N Engl J Med. 1994; 330: 877-884
        • Lv J.
        • Ehteshami P.
        • Sarnak M.J.
        • et al.
        Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis.
        CMAJ. 2013; 185: 949-957
        • Wright J.T.
        • Bakris G.
        • Greene T.
        • et al.
        Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
        JAMA. 2002; 288: 2421-2431
        • Peralta C.A.
        • McClure L.A.
        • Scherzer R.
        • et al.
        Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: a post hoc analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial.
        Circulation. 2016; 133: 584-591
        • Schrier R.W.
        • Abebe K.Z.
        • Perrone R.D.
        • et al.
        Blood pressure in early autosomal dominant polycystic kidney disease.
        N Engl J Med. 2014; 371: 2255-2266
        • Wright Jr., J.T.
        • Williamson J.D.
        • Whelton P.K.
        • et al.
        • SPRINT Research Group
        A randomized trial of intensive versus standard blood-pressure control.
        N Engl J Med. 2015; 373: 2103-2116
        • Cheung A.K.
        • Rahman M.
        • Reboussin D.M.
        • et al.
        Effects of intensive BP control in CKD.
        J Am Soc Nephrol. 2017; 28: 2812-2823
        • Malhotra R.
        • Siew E.D.
        Biomarkers for the early detection and prognosis of acute kidney injury.
        Clin J Am Soc Nephrol. 2017; 12: 149-173
        • Peralta C.A.
        • Katz R.
        • Bonventre J.V.
        • et al.
        Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA).
        Am J Kidney Dis. 2012; 60: 904-911
        • Scherzer R.
        • Lin H.
        • Abraham A.
        • et al.
        Use of urine biomarker-derived clusters to predict the risk of chronic kidney disease and all-cause mortality in HIV-infected women.
        Nephrol Dial Transplant. 2016; 31: 1478-1485
        • Ambrosius W.T.
        • Sink K.M.
        • Foy C.G.
        • et al.
        The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).
        Clin Trials. 2014; 11: 532-546
        • Jotwani V.
        • Scherzer R.
        • Abraham A.
        • et al.
        Association of urine alpha1-microglobulin with kidney function decline and mortality in HIV-infected women.
        Clin J Am Soc Nephrol. 2015; 10: 63-73
        • Parikh C.R.
        • Jani A.
        • Mishra J.
        • et al.
        Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation.
        Am J Transplant. 2006; 6: 1639-1645
        • Waikar S.S.
        • Sabbisetti V.
        • Ärnlöv J.
        • et al.
        Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies.
        Nephrol Dial Transplant. 2016; 31: 1460-1470
        • Park M.
        • Katz R.
        • Shlipak M.G.
        • et al.
        Urinary markers of fibrosis and risk of cardiovascular events and death in kidney transplant recipients: the FAVORIT Trial.
        Am J Transplant. 2017; 17: 2640-2649
        • Schmidt I.M.
        • Hall I.E.
        • Kale S.
        • et al.
        Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function.
        J Am Soc Nephrol. 2013; 24: 309-319
        • Ix J.H.
        • Katz R.
        • Bansal N.
        • et al.
        Urine fibrosis markers and risk of allograft failure in kidney transplant recipients: a case-cohort ancillary study of the FAVORIT Trial.
        Am J Kidney Dis. 2017; 69: 410-419
        • Nadkarni G.N.
        • Rao V.
        • Ismail-Beigi F.
        • et al.
        Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: the ACCORD Trial.
        Clin J Am Soc Nephrol. 2016; 11: 1343-1352
        • Hall I.E.
        • Yarlagadda S.G.
        • Coca S.G.
        • et al.
        IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation.
        J Am Soc Nephrol. 2010; 21: 189-197
        • Puthumana J.
        • Hall I.E.
        • Reese P.P.
        • et al.
        YKL-40 associates with renal recovery in deceased donor kidney transplantation.
        J Am Soc Nephrol. 2017; 28: 661-670
        • Cherney D.Z.
        • Perkins B.A.
        • Soleymanlou N.
        • et al.
        Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
        Circulation. 2014; 129: 587-597
        • Tang H.
        • Li D.
        • Zhang J.
        • et al.
        Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
        Diabetes Obes Metab. 2017; 19: 1106-1115
        • Wanner C.
        • Inzucchi S.E.
        • Lachin J.M.
        • et al.
        Empagliflozin and progression of kidney disease in type 2 diabetes.
        N Engl J Med. 2016; 375: 323-334
        • Nadkarni G.N.
        • Chauhan K.
        • Rao V.
        • et al.
        Effect of intensive blood pressure lowering on kidney tubule injury: findings from the ACCORD Trial study participants.
        Am J Kidney Dis. 2018; 73: 31-38